The University of Chicago Header Logo

Connection

Ryan Widau to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Ryan Widau has written about Dose-Response Relationship, Drug.
Ryan Widau
Connection Strength
0.032
Dose-Response Relationship, Drug
  1. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019 08; 20(8):1109-1123.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.